![]() |
市场调查报告书
商品编码
1722750
血气和电解质分析仪市场报告(按产品类型(分析仪、耗材)、设备(台式、便携式)、最终用户(医院、诊所、门诊手术中心等)和地区)2025 年至 2033 年Blood Gas and Electrolyte Analyzer Market Report by Product Type (Analyzers, Consumables), Modality (Benchtop, Portable), End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2025-2033 |
2024年全球血气和电解质分析仪市场规模达22亿美元。展望未来, IMARC Group预计到2033年市场规模将达到37亿美元,2025-2033年期间的成长率(CAGR)为5.37%。心血管併发症、癌症和糖尿病等各种慢性疾病的发病率不断上升,先进技术的融合日益紧密以减小设备尺寸并提高准确性,以及即时诊断(POC)检测服务的采用率不断上升,这些都是推动市场增长的一些因素。
血气电解质分析仪是指用于测量全血样本中血气(二氧化碳和氧气的分压)、pH值、电解质和代谢物等各种参数的医疗设备。它们被广泛用于检测代谢失衡以及测量肾臟和心臟功能。它们还有助于确定血液中异常的电解质水平、氧气或二氧化碳交换水平以及患者的酸碱平衡。此外,它们还有助于识别糖尿病、血管出血和药物消耗。近年来,血液气体和电解质分析仪因其易于使用、经济高效、准确且快速出结果而在临床诊断实验室和重症监护室中广受欢迎。
血气和电解质分析仪可以简化工作流程,最大限度地减少错误,只需最低限度的维护,并快速提供准确的结果。因此,重症监护室 (ICU)、手术室和急诊室的患者数量的增加是推动市场成长的主要因素。除此之外,糖尿病和心血管疾病等慢性疾病的广泛流行以及更容易患上这些疾病的老年人口的增长也增加了对产品的需求。此外,对高吞吐量、整合和自动化系统的需求也显着增加。同时,血液气体和电解质分析仪与实验室资讯系统和电子病历的日益融合,简化了工作流程,并能够有效监测患者的健康状况,从而促进了市场的成长。此外,一些领先的公司正在大力投资开发易于使用和操作且维护要求最低的便携式血气和电解质分析仪。其他因素,包括对即时检验 (POCT) 的偏好转变、医疗保健行业的发展、技术进步、产品创新以及广泛的研发 (R&D) 活动,也创造了良好的市场前景。
The global blood gas and electrolyte analyzer market size reached USD 2.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 5.37% during 2025-2033. The growing occurrence of various chronic illnesses like cardiovascular complications, cancer, and diabetes, increasing integration of advanced technologies to decrease the size of devices and enhance accuracy, and rising adoption of point-of-care (POC) testing services are some of the factors impelling the growth of the market.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.